Frequently Asked Questions

Read the Evidence Yourself

We encourage patients to review the original research and recommendations used when discussing menopausal hormone therapy. The following resources come from major medical organizations, government agencies, and peer-reviewed medical journals.

The Menopause Society — Hormone Therapy Position Statement

The Menopause Society states that hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and has been shown to prevent bone loss and fractures. For women younger than 60 or within approximately 10 years of menopause onset who do not have contraindications, the benefit-risk ratio is generally favorable.

The Menopause Society — Position Statements

2022 Hormone Therapy Position Statement — PubMed

American College of Obstetricians and Gynecologists — Hormone Therapy for Menopause

ACOG explains the established benefits of hormone therapy, including treatment of hot flashes and night sweats, vaginal symptoms, and prevention of early menopausal bone loss. ACOG also discusses cardiovascular risk, blood-clot risk, age, timing, and individualized treatment decisions.

ACOG — Hormone Therapy for Menopause

ACOG — Hormone Therapy and Early Menopause

Women experiencing menopause unusually early may have increased long-term health risks related to estrogen deficiency. ACOG discusses why hormone therapy is commonly recommended for appropriate women experiencing early menopause.

ACOG — Do I Really Need Hormone Therapy if I Have Early Menopause?

Women’s Health Initiative — Long-Term Mortality

This JAMA analysis followed women from the randomized Women’s Health Initiative hormone-therapy trials for approximately 18 years.

Overall, menopausal hormone therapy was not associated with increased all-cause mortality, cardiovascular mortality, or cancer mortality.

JAMA — Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specific Mortality

PubMed — WHI Long-Term Mortality Study

ELITE Trial — Starting Estrogen Earlier vs Later

The ELITE randomized trial specifically examined whether the cardiovascular effects of estradiol depend on how soon therapy is started after menopause.

Women who began estradiol within six years of menopause experienced significantly slower progression of carotid artery wall thickening, a marker of subclinical atherosclerosis. The same effect was not seen among women starting estradiol 10 or more years after menopause.

New England Journal of Medicine — Vascular Effects of Early Versus Late Postmenopausal Treatment With Estradiol

PubMed — ELITE Trial

Danish Osteoporosis Prevention Study

This randomized study followed healthy women who started hormone therapy soon after menopause and examined cardiovascular outcomes.

BMJ — Effect of Hormone Replacement Therapy on Cardiovascular Events in Recently Postmenopausal Women

Women’s Health Initiative — Breast Cancer Outcomes

This long-term randomized-trial follow-up is particularly useful because it demonstrates why all hormone therapy should not be discussed as though every formulation carries identical breast-cancer risk.

The WHI found different outcomes for estrogen alone compared with conjugated estrogen combined with medroxyprogesterone acetate.

JAMA — Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality

Free Full-Text Version — NIH/PubMed Central

CDC — Heart Disease and Women

Heart disease remains a major cause of death among women in the United States. Understanding cardiovascular risk before, during, and after the menopause transition is an important part of women’s preventive health care.

CDC — Leading Causes of Death in Females

CDC — Heart Disease Facts and Statistics

USPSTF — An Important Distinction

The U.S. Preventive Services Task Force recommends against prescribing systemic hormone therapy solely for the primary prevention of chronic disease in asymptomatic postmenopausal women.

However, the USPSTF specifically states that this recommendation does not apply to hormone therapy being used to treat menopausal symptoms such as hot flashes or vaginal dryness.

This distinction is important when interpreting recommendations about HRT.

USPSTF — Menopausal Hormone Therapy for Primary Prevention of Chronic Conditions

Additional Patient-Friendly Resource

The American College of Obstetricians and Gynecologists provides additional patient education covering who may benefit from hormone therapy, who may not be a candidate, and how risks differ based on an individual’s health history.

ACOG Patient Education — Hormone Therapy for Menopause

A Note About Online Information

Hormone therapy is a complex area of medicine. A single headline, social-media post, or study should not be used to determine whether treatment is appropriate for an individual woman.

When reviewing research, important questions include:

• How old were the women studied?
• How many years had they been menopausal when treatment started?
• Was estrogen taken orally or through the skin?
• Was estrogen used alone or with a progestogen?
• Which estrogen and progestogen formulations were studied?
• Did the women have preexisting cardiovascular or metabolic risk factors?
• Was the study randomized or observational?
• Was the outcome a symptom, laboratory marker, cardiovascular event, cancer diagnosis, fracture, or death?

These differences explain why apparently conflicting HRT studies may actually be studying very different groups of women and different forms of hormone therapy.

Our Approach

Our goal is not to convince every patient to use hormone therapy.

Our goal is to help each woman understand the available evidence, her individual risks and potential benefits, and the alternatives available so she can make an informed decision about her health.

Hormone therapy is individualized and is not appropriate for everyone.

Does Vitalis Integrative Health Accept Insurance?

Yes. Vitalis Integrative Health is currently in-network with UnitedHealthcare (UHC) for eligible patients in Kansas and Texas.

We are actively working to expand our insurance network, and additional insurance plans may be accepted in the future.

Have a different insurance plan?
You may still be able to use your insurance benefits if your plan includes out-of-network coverage. We can submit a claim to your insurance company on your behalf for eligible services.

For out-of-network visits:

• The self-pay visit fee is due at the time of service.
• We will submit the insurance claim on your behalf when applicable.
• If your insurance company pays Vitalis Integrative Health for the covered visit, the applicable amount you paid for that visit will be refunded to you.
• Insurance reimbursement is not guaranteed. Coverage, deductibles, coinsurance, and out-of-network benefits vary by individual plan.
• The amount billed to insurance may differ from our self-pay rate.

We recommend contacting your insurance company before your appointment to confirm your specific benefits and whether your plan includes out-of-network coverage.

Please note: Being insured by UHC does not automatically guarantee that every UHC plan or service is covered. Network participation and benefits vary by individual plan, and patients should verify eligibility and coverage directly with their insurance carrier.

Vitalis Integrative Health provides personalized telehealth care for adults and families, combining primary care with women’s health, hormone management, metabolic health, and wellness services.

Services include:

Primary & Acute Care

• Virtual primary care visits
• Sick visits and treatment of common acute conditions
• Medication management and refills
• Chronic condition management
• Preventive health and wellness evaluations
• Laboratory testing and review
• Imaging and specialist referrals when appropriate

Women’s Health & Hormone Care

• Perimenopause and menopause evaluations
• Menopausal hormone therapy (HRT)
• Estrogen, progesterone, and testosterone management when clinically appropriate
• Evaluation of fatigue, sleep changes, brain fog, mood changes, low libido, vaginal symptoms, and other symptoms associated with the menopause transition
• Bone, cardiovascular, and metabolic health considerations during midlife
• Ongoing hormone monitoring and treatment adjustments

Metabolic & Weight Management

• Medical weight-management consultations
• Evaluation and treatment of insulin resistance and metabolic health concerns
• GLP-1 medication management when medically appropriate
• Nutrition, lifestyle, and weight-wellness support
• Laboratory monitoring

Thyroid & Metabolic Health

• Thyroid evaluation and laboratory review
• Management of appropriate thyroid conditions
• Evaluation of symptoms that may have hormonal, metabolic, nutritional, or other underlying causes

Mental Health

• Evaluation and treatment of common anxiety and depressive disorders
• ADHD screening and evaluation
• Medication management when appropriate
• Referrals for therapy, psychiatry, or specialty care when indicated

Sexual & Intimate Health

• Evaluation of low libido and sexual health concerns
• Vaginal and genitourinary symptoms associated with menopause
• Hormonal contributors to sexual health concerns
• Individualized treatment options when appropriate

Specialty Wellness Services

• Evidence-informed wellness consultations
• Nutritional and supplement guidance
• Peptide education and therapy when legally and clinically appropriate
• Individualized health optimization plans

Care From the Comfort of Home

Vitalis Integrative Health is a telehealth-based practice, allowing patients to receive personalized care without the inconvenience of traveling to a traditional office.

When laboratory testing, imaging, or an in-person specialist evaluation is necessary, appropriate orders or referrals can be provided.

Our approach is centered on individualized, evidence-informed care. Treatment recommendations are based on your medical history, symptoms, laboratory findings, risk factors, personal preferences, and health goals.

Not every patient needs medication, hormones, supplements, or weight-loss treatment. Our goal is to determine what is appropriate for you and to help you understand your options so you can participate confidently in decisions about your health.

Hormone therapy has been one of the most misunderstood areas of women’s health. Many women still remember headlines from more than 20 years ago suggesting that menopausal hormone therapy was broadly dangerous. Since then, longer follow-up, additional randomized trials, and a better understanding of age, timing, route of administration, formulation, and individual health risks have substantially changed how menopause specialists evaluate hormone therapy.

The goal of this page is not to convince every woman to take hormone therapy. Hormone therapy is not appropriate for everyone. Instead, the goal is to help patients understand what current evidence shows so they can make an informed decision based on their individual symptoms, health history, age, risk factors, preferences, and goals.

What major menopause organizations currently say

The Menopause Society states that hormone therapy remains the most effective treatment for menopausal hot flashes and night sweats, is effective for genitourinary syndrome of menopause, and has been shown to prevent bone loss and fractures.

Most importantly, the Society states that in women who are:

younger than 60 years old OR within approximately 10 years of menopause onset, and who do not have contraindications to hormone therapy, the benefit-risk ratio is generally favorable.

The risks become less favorable when systemic hormone therapy is first initiated substantially later—particularly after age 60 or more than 10 years after menopause.

Source: The Menopause Society 2022 Hormone Therapy Position Statement. (PubMed)

ACOG similarly recognizes systemic estrogen as the most effective treatment for hot flashes and night sweats and confirms that estrogen helps protect against the rapid bone loss that occurs around menopause. (ACOG)

Why Timing Matters

One of the most important concepts to emerge from menopause research is the timing hypothesis.

Starting estrogen near the menopause transition may affect the cardiovascular system differently than starting estrogen for the first time 10, 15, or 20 years after menopause.

This distinction matters because many participants in the original Women’s Health Initiative were substantially older than women who typically seek treatment for menopausal symptoms. The average participant in WHI was approximately 63 years old.

A healthy 48-year-old experiencing early menopause should therefore not automatically be assumed to have the same risk profile as a woman beginning systemic hormone therapy at 70.

The ELITE randomized clinical trial directly investigated this question.

Researchers studied healthy women who were either:

• less than 6 years beyond menopause, or
• 10 or more years beyond menopause.

Among women who started estradiol within six years of menopause, progression of carotid artery wall thickening—a marker of subclinical atherosclerosis—was significantly slower with estradiol than with placebo.

The same benefit was not seen when estrogen was started 10 or more years after menopause.

This supports the concept that when hormone therapy is initiated may be as important as whether it is used. (New England Journal of Medicine)

Heart Health

Heart disease remains the leading cause of death among women in the United States. CDC data show that approximately 1 in 5 female deaths is attributable to heart disease. (CDC)

Menopause occurs during a period when several cardiovascular risk factors often become less favorable, including changes in body composition, glucose regulation, blood pressure and cholesterol.

Hormone therapy should not be prescribed solely as a medication to prevent heart disease. Major organizations remain appropriately cautious about making that recommendation.

However, the research regarding younger, recently menopausal women is considerably more reassuring than the early interpretation of WHI suggested.

ACOG notes that some research suggests combined hormone therapy may protect against heart attacks in women who start treatment within 10 years of menopause and before age 60, and that the potential effect may be greater with estrogen alone. (ACOG)

In the randomized Danish Osteoporosis Prevention Study, 1,006 healthy women ages 45–58 who were recently menopausal were randomized to hormone therapy or no treatment.

After 10 years, women who began HRT early after menopause experienced significantly fewer events in the combined outcome of:

death + myocardial infarction + heart failure.

The investigators did not observe a significant increase in breast cancer or stroke during the study.

This study is important but should not be interpreted by itself as proof that HRT prevents cardiovascular disease. It is one piece of a larger body of evidence supporting the importance of age and timing. (BMJ)

Does HRT Help Women Live Longer?

This is an area where wording matters.

It would be inaccurate to promise that hormone therapy will extend a woman’s life.

However, randomized-trial data also do not show that appropriately prescribed menopausal hormone therapy shortens women’s lives overall.

Long-term follow-up of the Women’s Health Initiative found no significant increase in:

• all-cause mortality
• cardiovascular mortality
• cancer mortality

among women randomized to menopausal hormone therapy compared with placebo during approximately 18 years of cumulative follow-up. (JAMA Network)

Interestingly, several analyses suggest that women who begin hormone therapy younger may experience a mortality benefit.

A meta-analysis of 30 randomized trials involving more than 26,000 women found no mortality difference when women of all ages were combined.

But among trials in which the average participant was younger than 60, hormone therapy was associated with approximately a 39% lower odds of death during the trial periods studied.

OR 0.61; 95% CI 0.39–0.95. (PubMed)

Another systematic review of 43 randomized trials similarly found no overall mortality benefit when all women were grouped together. However, among trials where treatment began before age 60 or within 10 years of menopause, hormone therapy was associated with lower mortality:

RR 0.70; 95% CI 0.52–0.95. (PubMed)

These findings are encouraging and support the importance of timing, but they are not sufficient to prescribe HRT solely for longevity.

Bone Health: One of the Clearest Benefits

Estrogen plays a major role in maintaining bone.

As estrogen declines during menopause, bone turnover accelerates and women can lose bone density rapidly.

Hormone therapy has consistently been shown to:

reduce bone loss, increase bone mineral density, and reduce fractures.

In the Women’s Health Initiative randomized trial of estrogen plus progestin, fractures occurred in:

8.6% of women receiving hormone therapy versus 11.1% receiving placebo.

That represented approximately a 24% relative reduction in fracture risk.

Hip bone mineral density also increased substantially with treatment. (JAMA Network)

In the WHI estrogen-only trial, estrogen was also associated with significantly fewer total fractures:

HR 0.72, representing approximately a 28% relative risk reduction. (JAMA Network)

For women experiencing menopause unusually early, preservation of bone health becomes particularly important.

Blood Sugar and Diabetes

One less-discussed finding from randomized hormone-therapy trials is the effect on diabetes.

In the Women’s Health Initiative:

Women randomized to estrogen plus progestin experienced fewer new diagnoses of diabetes than women receiving placebo:

HR 0.81 — approximately a 19% relative reduction.

Women randomized to estrogen alone also experienced fewer new diabetes diagnoses:

HR 0.86 — approximately a 14% relative reduction. (JAMA Network)

This does not mean HRT should be prescribed as diabetes treatment or prevention.

It does mean that the commonly repeated idea that hormone therapy is uniformly harmful to metabolic health is not supported by randomized-trial evidence.

Hot Flashes and Night Sweats

This is where the evidence is strongest.

Systemic estrogen, with progesterone/progestogen when appropriate, remains the most effective available treatment for menopausal vasomotor symptoms, including:

• hot flashes
• night sweats
• menopause-related sleep disruption

Both ACOG and The Menopause Society recognize hormone therapy as the most effective treatment for these symptoms. (ACOG)

For many women, relieving severe night sweats and hot flashes also indirectly improves sleep, concentration, mood, daily functioning, exercise tolerance, relationships and overall quality of life.

Vaginal and Urinary Health

Loss of estrogen affects much more than the menstrual cycle.

Estrogen receptors are present throughout vaginal, vulvar, urethral and bladder tissues.

Declining estrogen can contribute to what is now called genitourinary syndrome of menopause (GSM).

Symptoms may include:

• vaginal dryness
• burning or irritation
• painful intercourse
• decreased vaginal elasticity
• urinary urgency
• urinary frequency
• recurrent urinary tract infections

The Menopause Society recognizes vaginal estrogen as an effective treatment for genitourinary symptoms and notes that very little estrogen enters systemic circulation with low-dose local therapy. (The Menopause Society)

Breast Cancer: The Details Matter

Patients are frequently told simply that “estrogen causes breast cancer.”

The research is considerably more nuanced.

The Women’s Health Initiative studied two different groups.

Estrogen alone

Women who had previously undergone hysterectomy were randomized to conjugated equine estrogen alone or placebo.

After more than 20 years of cumulative follow-up, women previously randomized to estrogen alone had:

22% lower breast cancer incidence

HR 0.78

and

40% lower breast cancer mortality

HR 0.60

compared with placebo. (JAMA Network)

Estrogen + medroxyprogesterone acetate

Women with a uterus received conjugated equine estrogen plus the synthetic progestin medroxyprogesterone acetate (MPA).

This regimen was associated with higher breast cancer incidence:

HR 1.28.

Breast-cancer mortality was not statistically significantly different in the long-term analysis. (JAMA Network)

This is one reason it is inaccurate to treat every formulation of hormone therapy as though it carries identical risks.

Estrogen alone, estrogen combined with synthetic progestins, estrogen combined with micronized progesterone, oral estrogen, transdermal estradiol, dose, duration and individual patient characteristics are not interchangeable variables.

Blood Clots: Oral and Transdermal Estrogen Are Not Identical

Blood-clot risk is another area where route of administration matters.

ACOG notes that oral estrogen may have a prothrombotic effect, whereas transdermal estrogen has little or no effect on several prothrombotic markers.

ACOG therefore recommends considering the potential “thrombosis-sparing” properties of transdermal estrogen when individualizing therapy. (ACOG)

In one large case-control study cited by ACOG, the odds ratio for venous thromboembolism compared with nonusers was:

Oral estrogen: OR 4.2

Transdermal estrogen: OR 0.9

Observational studies cannot establish the same level of causality as randomized trials, but these findings help explain why route of administration is considered during individualized risk assessment. (ACOG)

Blood-clot risk is particularly important when a woman has additional risk factors such as prior VTE, thrombophilia, obesity, prolonged immobilization or certain cardiovascular conditions.

Early or Premature Menopause Is Different

Women who lose ovarian hormone production unusually early should not automatically be treated like a woman experiencing natural menopause at approximately age 51.

Premature ovarian insufficiency and early menopause are associated with long-term health consequences related to prolonged estrogen deficiency, including loss of bone density.

ACOG considers hormone replacement an important part of long-term management of primary ovarian insufficiency and generally recommends treatment, absent contraindications, until approximately the average age of natural menopause. (ACOG)

What HRT Cannot Promise

Evidence-based menopause care also means being clear about what hormone therapy has not been proven to do.

Hormone therapy should not currently be promised to:

• prevent every heart attack
• prevent dementia
• prevent every chronic disease
• guarantee weight loss
• prevent breast cancer
• guarantee a longer lifespan

The U.S. Preventive Services Task Force recommends against using systemic menopausal hormone therapy solely for primary prevention of chronic disease in otherwise asymptomatic postmenopausal women. Importantly, that recommendation specifically does not address hormone therapy being used to treat menopausal symptoms, nor does it apply to women with premature or surgical menopause. (USPSTF)

This distinction is frequently lost in online discussions.

Who Usually Has the Most Favorable Risk-Benefit Profile?

In general, the evidence is most reassuring for healthy women who:

• are experiencing bothersome perimenopausal or menopausal symptoms
• are younger than approximately 60
• are within approximately 10 years of menopause
• do not have a personal history of estrogen-sensitive cancer
• do not have unexplained vaginal bleeding
• do not have active or significant liver disease
• do not have a previous heart attack or stroke
• do not have a previous blood clot or another major contraindication

Even among women who appear low risk, treatment should be individualized.

A woman’s age, menstrual history, uterus status, symptoms, blood pressure, metabolic health, breast history, family history, migraine history, cardiovascular history, clotting history, medications and personal preferences may influence the safest treatment approach.

Individualized Care Matters

Hormone therapy is not a one-size-fits-all medication.

The benefit-risk profile can differ based on:

Age

Time since menopause

Symptoms

Estrogen dose

Oral versus transdermal delivery

Whether progesterone or a progestin is needed

Which progesterone/progestogen is used

Whether the patient has a uterus

Personal and family medical history

Duration of therapy

This is why menopause care should involve an individualized discussion rather than a universal rule that “everyone should take hormones” or “hormones are dangerous.”

Both statements oversimplify the evidence.

The Bottom Line

For appropriately selected healthy women—particularly those younger than 60 or within approximately 10 years of menopause who have no contraindications—modern evidence supports a generally favorable benefit-risk profile when hormone therapy is being used for appropriate indications.

The clearest established benefits include:

• powerful relief of hot flashes and night sweats
• improvement of genitourinary symptoms
• prevention of menopausal bone loss
• reduction in fracture risk

Randomized trials have additionally demonstrated favorable effects on diabetes incidence, and cardiovascular research supports the importance of beginning therapy closer to menopause rather than decades later.

Some randomized trials and meta-analyses also suggest lower mortality when hormone therapy is initiated in younger women, although the evidence is not strong enough to recommend hormone therapy solely for the purpose of extending life or preventing cardiovascular disease.

The right question is therefore usually not:

“Is hormone therapy good or bad?”

A better question is:

“For this particular woman, at this particular age and stage of menopause, with her individual medical history and goals, do the expected benefits outweigh the potential risks?”

That is the basis of individualized, evidence-based menopause care.

Trusted Sources & Further Reading

The Menopause Society
2022 Hormone Therapy Position Statement and patient education on hormone therapy. (PubMed)

American College of Obstetricians and Gynecologists (ACOG)
Hormone Therapy for Menopause. (ACOG)

Women’s Health Initiative — JAMA
Long-term mortality following randomized menopausal hormone therapy. (JAMA Network)

Women’s Health Initiative — JAMA
Long-term breast cancer incidence and mortality according to estrogen alone versus estrogen plus medroxyprogesterone acetate. (JAMA Network)

ELITE Trial — New England Journal of Medicine
Early versus late initiation of estradiol and progression of atherosclerosis. (New England Journal of Medicine)

Danish Osteoporosis Prevention Study — BMJ
Cardiovascular outcomes after hormone therapy initiated early after menopause. (BMJ)

Centers for Disease Control and Prevention
Women and heart disease statistics. (CDC)

U.S. Preventive Services Task Force
Hormone therapy and primary prevention of chronic disease. (USPSTF)

Important Medical Disclaimer

This information is provided for general educational purposes and should not be interpreted as a recommendation that every woman use hormone therapy. Hormone therapy has potential benefits and risks, and treatment decisions should be individualized based on symptoms, age, medical history, family history, contraindications, personal preferences, and ongoing risk assessment.

Information on this page is not a substitute for individualized medical evaluation or emergency care.

Vitalis Integrative Health makes it easy to receive personalized healthcare from the comfort and privacy of your home.

Your visit is completed through a secure virtual appointment where we discuss your symptoms, medical history, medications, health concerns, and goals. When medically appropriate, laboratory testing, imaging, prescriptions, and specialist referrals can be ordered without requiring an in-office visit.

After your results are available, they are reviewed as part of your care plan, and treatment recommendations are individualized based on your specific needs.

While many conditions can be safely evaluated and managed through telehealth, some concerns require an in-person examination, urgent care, or emergency evaluation. If that occurs, you will be advised on the appropriate next step.

Convenient care doesn’t have to mean rushed care. Our goal is to provide accessible, thorough, and personalized healthcare while helping you understand your options and take an active role in your health.